Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab + Chemotherapy in Resectable Merkel Cell Carcinoma (MERCURY)
NCT05594290Phase 2Active, not recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in Merkel cell carcinoma (MCC), sponsored by Gruppo Oncologico Nord Ovest. Started Dec 2022; status: active, not recruiting.
02
Drugs
retifanlimab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05594290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594290.